Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.
作者信息
Nuño Laura, Novella Navarro Marta, Bonilla Gema, Franco-Gómez Karen, Aguado Pilar, Peiteado Diana, Monjo Irene, Tornero Carolina, Villalba Alejandro, Miranda-Carus Maria-Eugenia, De Miguel Eugenio, Bogas Patricia, Castilla-Plaza Ana, Bernad-Pineda Miguel, García-Lorenzo Elena, Rodríguez-Araya Tamara, Balsa Alejandro
机构信息
Rheumatology, La Paz University Hospital, Madrid, Spain
Rheumatology, La Paz University Hospital, Madrid, Spain.
出版信息
Ann Rheum Dis. 2020 Dec;79(12):1659-1661. doi: 10.1136/annrheumdis-2020-218054. Epub 2020 Jun 30.
Abstract
摘要
相似文献
1
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.一组患有风湿性疾病的COVID-19患者的临床病程、严重程度和死亡率。
Ann Rheum Dis. 2020 Dec;79(12):1659-1661. doi: 10.1136/annrheumdis-2020-218054. Epub 2020 Jun 30.
2
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.2019 年冠状病毒病（COVID-19）在自身免疫和炎症性疾病中的表现：不良结局的临床特征。
Rheumatol Int. 2020 Oct;40(10):1593-1598. doi: 10.1007/s00296-020-04676-4. Epub 2020 Aug 13.
3
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.COVID-19 住院患者合并慢性炎症和自身免疫性风湿性疾病的临床结局：一项多中心匹配队列研究。
Ann Rheum Dis. 2020 Dec;79(12):1544-1549. doi: 10.1136/annrheumdis-2020-218296. Epub 2020 Aug 12.
4
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
5
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.接受生物和合成靶向治疗的风湿性疾病患者中COVID-19的临床特征和结局
Ann Rheum Dis. 2020 Jul;79(7):988-990. doi: 10.1136/annrheumdis-2020-217948. Epub 2020 Jun 5.
6
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.德国炎症性风湿病（IRD）患者感染 SARS-CoV-2 的国家登记处（ReCoVery）：了解 IRD 患者 SARS-CoV-2 感染临床病程的快速可靠知识的宝贵手段。
RMD Open. 2020 Sep;6(2). doi: 10.1136/rmdopen-2020-001332.
7
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.COVID-19 患者伴系统性红斑狼疮，SARS-CoV-2 RNA 阳性复发后成功康复：病例报告及文献复习。
Clin Rheumatol. 2020 Sep;39(9):2803-2810. doi: 10.1007/s10067-020-05230-0. Epub 2020 Jul 28.
8
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.风湿性疾病患者 COVID-19 疾病严重程度的决定因素。
Clin Rheumatol. 2020 Sep;39(9):2789-2796. doi: 10.1007/s10067-020-05301-2. Epub 2020 Jul 27.
9
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series.COVID-19 与风湿性自身免疫性系统性疾病：一项大型意大利患者系列报告。
Clin Rheumatol. 2020 Nov;39(11):3195-3204. doi: 10.1007/s10067-020-05334-7. Epub 2020 Aug 27.
10
Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study.脊髓损伤患者感染新型冠状病毒肺炎的临床特征与预后：一项病例对照研究
Spinal Cord Ser Cases. 2020 Aug 4;6(1):69. doi: 10.1038/s41394-020-0319-0.
引用本文的文献
1
Effects of colchicine, interferon β, IVIG, tocilizumab and corticosteroids on COVID-19 patient survival from all presently available published clinical trials: A narrative review.秋水仙碱、干扰素β、静脉注射免疫球蛋白、托珠单抗和皮质类固醇对COVID-19患者生存的影响：基于所有现有已发表临床试验的叙述性综述。
Caspian J Intern Med. 2025 Mar 11;16(2):198-214. doi: 10.22088/cjim.16.2.198. eCollection 2025.
2
Patients with systemic autoimmune rheumatic diseases remain at risk for hospitalisation for COVID-19 infection in the Omicron era (2022-2024): a retrospective cohort study.在奥密克戎时代（2022 - 2024年），系统性自身免疫性风湿疾病患者因感染新冠病毒而住院的风险依然存在：一项回顾性队列研究。
RMD Open. 2025 Mar 5;11(1):e005114. doi: 10.1136/rmdopen-2024-005114.
3
The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.接受抗 CD20 治疗的淋巴瘤患者对 Covid-19 mRNA 疫苗接种的免疫反应。
Front Immunol. 2024 Sep 4;15:1433442. doi: 10.3389/fimmu.2024.1433442. eCollection 2024.
4
Systematic analysis for clinical characteristics and outcomes of IgG4-related disease patients during the COVID-19 pandemic.COVID-19 大流行期间 IgG4 相关疾病患者的临床特征和结局的系统分析。
Clin Rheumatol. 2024 Aug;43(8):2595-2606. doi: 10.1007/s10067-024-07033-z. Epub 2024 Jun 22.
5
COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases.免疫介导的炎症性疾病中的 COVID-19 疫苗接种与免疫抑制治疗
Vaccines (Basel). 2023 Dec 4;11(12):1813. doi: 10.3390/vaccines11121813.
6
COVID-19 vaccination of patients with chronic immune-mediated inflammatory disease.新型冠状病毒肺炎疫苗接种：慢性免疫介导的炎症性疾病患者
Adv Rheumatol. 2023 Nov 1;63(1):54. doi: 10.1186/s42358-023-00335-x.
7
Coronavirus Disease 2019 in Rheumatic Patients with Inflammatory Disorders: A Descriptive Study from a High Infection Incidence Region of Northern Spain.西班牙北部高感染率地区炎症性疾病风湿患者的2019冠状病毒病：一项描述性研究
Eur J Rheumatol. 2023 Oct;10(4):136-142. doi: 10.5152/eurjrheum.2023.21152.
8
COVID-19 in patients with rheumatological diseases in the Eastern Province of Saudi Arabia.沙特阿拉伯东部省份风湿性疾病患者的 COVID-19 。
J Med Life. 2023 Jun;16(6):873-882. doi: 10.25122/jml-2023-0037.
9
Clinical Course and Outcomes of COVID-19 Infection in Patients Treated with Rituximab: A Tertiary Care Center Experience.接受利妥昔单抗治疗的COVID-19感染患者的临床病程及结局：一家三级医疗中心的经验
Open Access Rheumatol. 2023 Aug 28;15:145-159. doi: 10.2147/OARRR.S424316. eCollection 2023.
10
Immune response after SARS-CoV-2 vaccination in patients with inflammatory immune-mediated diseases receiving immunosuppressive treatment.接受免疫抑制治疗的炎症性免疫介导疾病患者接种新型冠状病毒2疫苗后的免疫反应。
Allergy Asthma Clin Immunol. 2023 Aug 19;19(1):71. doi: 10.1186/s13223-023-00832-0.
本文引用的文献
1
A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe.欧洲一家大型教学医院的新冠病毒肺炎患者队列。
J Clin Med. 2020 Jun 4;9(6):1733. doi: 10.3390/jcm9061733.
2
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries.风湿性疾病与2019冠状病毒病：来自2019冠状病毒病全球风湿病联盟医疗服务提供者登记处的初步数据。
Lancet Rheumatol. 2020 May;2(5):e250-e253. doi: 10.1016/S2665-9913(20)30095-3. Epub 2020 Apr 16.
3
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.一系列接受免疫抑制靶向治疗的慢性关节炎患者的 COVID-19 临床病程。
Ann Rheum Dis. 2020 May;79(5):667-668. doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2.
4
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?COVID-19、细胞因子和免疫抑制：我们能从严重急性呼吸综合征中学到什么？
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342. doi: 10.55563/clinexprheumatol/xcdary. Epub 2020 Mar 22.
5
Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.合并症的患病率及其对 SARS-CoV-2 感染患者的影响：系统评价和荟萃分析。
Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12.
6
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
Zotero 插件